Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT plus CROSS chemoradiotherapy for oligometastatic oesophageal or gastro-oesophageal junction adenocarcinoma
2020-003605-55Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Nov 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin, docetaxel, carboplatin and 1 more in adenocarcinoma of the lower esophagus and gastroesophageal adenocarcinoma, sponsored by Erasmus MC. Primary endpoint: Tolerability of combined regimens. Started Nov 2020; status: completed.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelcarboplatin
03
Conditions
adenocarcinoma of the lower esophagusgastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2020-003605-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003605-55.